SCHEMBL5344934

SCHEMBL5344934

CC(C)c1cccc2c(O)cc(=O)oc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.51
CA12 O43570 3/20 0.49
CA9 Q16790 3/20 0.49
CA1 P00915 2/20 0.49
CYP3A4 P08684 4/20 0.47
CYP1A2 P05177 3/20 0.47
KMT2A Q03164 3/20 0.47
CYP2C19 P33261 2/20 0.47
MEN1 O00255 2/20 0.47
POLB P06746 2/20 0.47
LMNA P02545 2/20 0.41
GABRA1 P14867 2/20 0.41
GABRB2 P47870 2/20 0.41
TSHR P16473 2/20 0.41
FAAH O00519 1/20 0.41
CA2 P00918 1/20 0.41
HPGD P15428 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
PTGS1 P23219 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15843030 0.82 KMT2A (0.55) CYP3A4CYP1A2KMT2ACYP2C19POLB
SCHEMBL30693881 0.79 MET (0.61) METCA12CA9CA1CYP3A4
SCHEMBL28480556 0.79 MET (0.61) METCA12CA9CA1CYP3A4
SCHEMBL2761835 0.78 MET (0.56) METCA12CA9CA1CYP3A4
SCHEMBL5338642 0.77 GABRA1 (0.44) METCA12CA9CA1CYP3A4
SCHEMBL5344800 0.75 MET (0.53) METCA12CA9CA1CYP3A4
SCHEMBL31323561 0.75 MET (0.56) METCA12CA9CA1CYP3A4
SCHEMBL25603792 0.75 MET (0.56) METCA12CA9CA1CYP3A4
SCHEMBL2761879 0.75 MET (0.56) METCA12CA9CA1CYP3A4
SCHEMBL10381209 0.75 MET (0.56) METCA12CA9CA1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080153872-A1 Bis-(Coumarin) Compounds With Anti-Inflammatory Activity PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2008-06-26 US disclosed
US-20080153872-A1 Bis-(Coumarin) Compounds With Anti-Inflammatory Activity PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2008-06-26 US disclosed
US-7208518-B2 Substituted furochromene compounds of antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2007-04-24 US disclosed
US-20060148890-A1 Substituted furochromene compounds of antiinflammatory action PLIVA-LSTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed
EP-1648901-A1 SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP disclosed
WO-2005010006-A1 SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153872-A1 Bis-(Coumarin) Compounds With Anti-Inflammatory Activity NOD1, NOD2, CASP1 MET 4268/4885CA12 2096/4885CA9 598/4885
US-20060148890-A1 Substituted furochromene compounds of antiinflammatory action LTC4S, CYP11B2, CYP11B1 MET 3947/4885CA12 3303/4885CA9 2752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.